{
    "clinical_study": {
        "@rank": "48590", 
        "arm_group": {
            "arm_group_label": "CBL0137", 
            "arm_group_type": "Experimental", 
            "description": "Dose Level 1: 10 mg/m2, IV (in the vein)\nDose Level 2: 20 mg/m2, IV (in the vein)\nDose Level 3: 30 mg/m2, IV (in the vein)\nDose Level 4: 40 mg/m2, IV (in the vein)\nDose Level 5: 50 mg/m2, IV (in the vein)\nDose Level 6: 62.5 mg/m2, IV (in the vein)"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the study is to determine the maximally tolerated dose and\n      recommended Phase 2 dose of CBL0137 when administered intravenously (IV) to patients with\n      metastatic or unresectable advanced solid malignancies or refractory lymphomas."
        }, 
        "brief_title": "A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas", 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients must have documented recurrent or refractory solid tumors, or refractory lymphomas;\n      patients enrolled in the dose-expansion part of the trial must have least one lesion that\n      may qualify as a target lesion based on the RECIST 1.1 criteria.  Following the provision of\n      signed informed consent, patients will be screened for entry into the study.  Screening\n      numbers will be assigned by the site.  Patients who do not meet entry criteria will not have\n      their screening data entered into the database."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histological or cytological evidence of a solid neoplasm or\n             lymphoma\n\n          -  Patients enrolled in the expansion cohort must have at least one measureable lesion\n             as defined by the RECIST 1.1 criteria\n\n          -  Patients must:\n\n               -  have metastatic or unresectable advanced solid tumors or refractory lymphomas\n                  that have recurred or progressed following standard therapy or\n\n               -  no longer be candidates for standard therapy or\n\n               -  have tumors for which there is no standard therapy\n\n          -  Patients must be ambulatory and have an ECOG Performance Score of 0 or 1;\n\n          -  Patients or their legal representative must be able to provide written informed\n             consent;\n\n          -  Patients must have adequate bone marrow reserve as evidenced by:\n\n               -  White Blood Cell Count (WBC) > 3,000/\u00b5L\n\n               -  Absolute Neutrophil Count (ANC) > 1,500/\u00b5L\n\n               -  Platelet count (PLT) > 100,000/\u00b5L\n\n               -  Hemoglobin (HGB) > 9.0 gm/dL (patients may be transfused to achieve this HGB\n                  level);\n\n          -  Patients must have adequate hepatic function as evidenced by:\n\n               -  Serum AST/ALT < 3X the upper limit of normal (ULN) for the reference lab (< 5X\n                  the ULN for patients with known hepatic metastases)\n\n               -  Serum bilirubin < 1.5 x the ULN for the reference lab;\n\n        Exclusion Criteria:\n\n          -  Patients with active infection or with a fever > 38.50 C within 3 days of the first\n             scheduled day of dosing;\n\n          -  Patients with primary CNS tumors or symptomatic CNS metastases who have not undergone\n             surgery and/or radiotherapy and/or who are not neurologically stable;\n\n          -  Patients with known hypersensitivity to any of the components of CBL0137;\n\n          -  Patients who are receiving concurrent investigational therapy; for patients who have\n             recently received investigational therapy, 5 half-lives must have elapsed between the\n             last dose of investigational drug and the first dose of CBL0137.  If the half-live is\n             unknown, 4 weeks must have elapsed between the last dose of investigational drug and\n             the first dose of CBL0137 (investigational therapy is defined as treatment for which\n             there is currently no regulatory authority approved indication in the United States);\n\n          -  Males with mean QTcF values of > 450 msec and females with QTcF values of > 470 msec\n             following 3 ECGs conducted 5 minutes apart from each other; patients who are known to\n             have congenital prolonged QT syndromes; or patients who are on medications known to\n             cause prolonged QT intervals on ECG;\n\n        Please speak with the PI for the complete Inclusion/Exclusion listing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01905228", 
            "org_study_id": "I137-101"
        }, 
        "intervention": {
            "arm_group_label": "CBL0137", 
            "description": "All doses are on Days 1, 8 and 15 of every 28 day cycle. Number of Cycles: 2 or until progression or unacceptable toxicity develops", 
            "intervention_name": "CBL0137", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Metastatic Advance Solid Neoplasms", 
            "Unresectable Advance Solid Neoplasms", 
            "Refractory Lymphomas"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Wen.Ma@RoswellPark.org", 
                    "last_name": "Wen W Ma, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Roswell Park Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Wen W Ma, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mahalingam@uthscsa.edu", 
                    "last_name": "Devalingam Mahalingam, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "CTRC at The University of Texas Healh Science Center at San Antonio"
                }, 
                "investigator": {
                    "last_name": "Devalingam Mahalingam, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas", 
        "overall_contact": {
            "email": "jvallet@cbiolabs.cm", 
            "last_name": "Jean Viallet, MD", 
            "phone": "716-849-6810"
        }, 
        "overall_official": [
            {
                "affiliation": "The University of Texas Health Science Center at San Antonio", 
                "last_name": "Devalingam Mahalingam, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Roswell Park Cancer Institue", 
                "last_name": "Wen W Ma, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To determine the maximally tolerated dose and recommended Phase 2 dose", 
            "safety_issue": "Yes", 
            "time_frame": "30 days after last dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01905228"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Incuron", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Incuron", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}